1-HydroxyPGE1 reduces infarction volume in mouse transient cerebral ischemia

Muzamil Ahmad, Sofiyan Saleem, Hean Zhuang, Abdullah Shafique Ahmad, Valentina Echeverria, Adam Sapirstein, Sylvain Doré

Research output: Contribution to journalArticle

Abstract

Differential neurological outcomes due to prostaglandin E2 activating G-protein-coupled prostaglandin E (EP) receptors have been observed. Here, we investigated the action of the EP4/EP3 agonist 1-hydroxyPGE1 (1-OHPGE1) in modulating transient ischemic brain damage. C57BL/6 mice were pretreated 50 min before transient occlusion of the middle cerebral artery with an intraventricular injection of 1-OHPGE1 (0.1, 0.2, 2.0 nmol/0.2 μL). Brain damage 4 days after reperfusion, as estimated by infarct volume, was significantly reduced by more than 19% with 1-OHPGE1 in the two higher-dose groups (P <0.05). To further address whether protection also was extended to neurons, primary mouse cultured neuronal cells were exposed to N-methyl-d-aspartate. Co-treatment with 1-OHPGE1 resulted in significant neuroprotection (P <0.05). To better understand potential mechanisms of action and to test whether changes in cyclic adenosine monophosphate (cAMP) levels and downstream signaling would be neuroprotective, we measured cAMP levels in primary neuronal cells. Brief exposure to 1-OHPGE1 increased cAMP levels more than twofold and increased the phosphorylation of extracellular-regulated kinases at positions Thr-202/Tyr-204. In a separate cohort of animals, 1-OHPGE1 at all doses tested produced no significant effect on the physiological parameters of core body temperature, mean arterial pressure and relative cerebral blood flow observed following drug treatment. Together, these results suggest that modulation of PGE2 receptors that increase cAMP levels and activate extracellular-regulated kinases 1/2 caused by treatment with 1-OHPGE1 can be protective against neuronal injury induced by focal ischemia.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalEuropean Journal of Neuroscience
Volume23
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Transient Ischemic Attack
Cyclic AMP
Infarction
Prostaglandin E Receptors
Cerebrovascular Circulation
Phosphotransferases
Intraventricular Injections
Middle Cerebral Artery Infarction
Brain
Body Temperature
Inbred C57BL Mouse
GTP-Binding Proteins
Dinoprostone
Aspartic Acid
Action Potentials
Reperfusion
Cultured Cells
Arterial Pressure
Therapeutics
Ischemia

Keywords

  • Agonist
  • EP receptors
  • Neuroprotection
  • PGE
  • Prostaglandins
  • Stroke

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

1-HydroxyPGE1 reduces infarction volume in mouse transient cerebral ischemia. / Ahmad, Muzamil; Saleem, Sofiyan; Zhuang, Hean; Ahmad, Abdullah Shafique; Echeverria, Valentina; Sapirstein, Adam; Doré, Sylvain.

In: European Journal of Neuroscience, Vol. 23, No. 1, 01.2006, p. 35-42.

Research output: Contribution to journalArticle

Ahmad, Muzamil ; Saleem, Sofiyan ; Zhuang, Hean ; Ahmad, Abdullah Shafique ; Echeverria, Valentina ; Sapirstein, Adam ; Doré, Sylvain. / 1-HydroxyPGE1 reduces infarction volume in mouse transient cerebral ischemia. In: European Journal of Neuroscience. 2006 ; Vol. 23, No. 1. pp. 35-42.
@article{80db6737362a41169b6ddbf8c8b52a41,
title = "1-HydroxyPGE1 reduces infarction volume in mouse transient cerebral ischemia",
abstract = "Differential neurological outcomes due to prostaglandin E2 activating G-protein-coupled prostaglandin E (EP) receptors have been observed. Here, we investigated the action of the EP4/EP3 agonist 1-hydroxyPGE1 (1-OHPGE1) in modulating transient ischemic brain damage. C57BL/6 mice were pretreated 50 min before transient occlusion of the middle cerebral artery with an intraventricular injection of 1-OHPGE1 (0.1, 0.2, 2.0 nmol/0.2 μL). Brain damage 4 days after reperfusion, as estimated by infarct volume, was significantly reduced by more than 19{\%} with 1-OHPGE1 in the two higher-dose groups (P <0.05). To further address whether protection also was extended to neurons, primary mouse cultured neuronal cells were exposed to N-methyl-d-aspartate. Co-treatment with 1-OHPGE1 resulted in significant neuroprotection (P <0.05). To better understand potential mechanisms of action and to test whether changes in cyclic adenosine monophosphate (cAMP) levels and downstream signaling would be neuroprotective, we measured cAMP levels in primary neuronal cells. Brief exposure to 1-OHPGE1 increased cAMP levels more than twofold and increased the phosphorylation of extracellular-regulated kinases at positions Thr-202/Tyr-204. In a separate cohort of animals, 1-OHPGE1 at all doses tested produced no significant effect on the physiological parameters of core body temperature, mean arterial pressure and relative cerebral blood flow observed following drug treatment. Together, these results suggest that modulation of PGE2 receptors that increase cAMP levels and activate extracellular-regulated kinases 1/2 caused by treatment with 1-OHPGE1 can be protective against neuronal injury induced by focal ischemia.",
keywords = "Agonist, EP receptors, Neuroprotection, PGE, Prostaglandins, Stroke",
author = "Muzamil Ahmad and Sofiyan Saleem and Hean Zhuang and Ahmad, {Abdullah Shafique} and Valentina Echeverria and Adam Sapirstein and Sylvain Dor{\'e}",
year = "2006",
month = "1",
doi = "10.1111/j.1460-9568.2005.04540.x",
language = "English (US)",
volume = "23",
pages = "35--42",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - 1-HydroxyPGE1 reduces infarction volume in mouse transient cerebral ischemia

AU - Ahmad, Muzamil

AU - Saleem, Sofiyan

AU - Zhuang, Hean

AU - Ahmad, Abdullah Shafique

AU - Echeverria, Valentina

AU - Sapirstein, Adam

AU - Doré, Sylvain

PY - 2006/1

Y1 - 2006/1

N2 - Differential neurological outcomes due to prostaglandin E2 activating G-protein-coupled prostaglandin E (EP) receptors have been observed. Here, we investigated the action of the EP4/EP3 agonist 1-hydroxyPGE1 (1-OHPGE1) in modulating transient ischemic brain damage. C57BL/6 mice were pretreated 50 min before transient occlusion of the middle cerebral artery with an intraventricular injection of 1-OHPGE1 (0.1, 0.2, 2.0 nmol/0.2 μL). Brain damage 4 days after reperfusion, as estimated by infarct volume, was significantly reduced by more than 19% with 1-OHPGE1 in the two higher-dose groups (P <0.05). To further address whether protection also was extended to neurons, primary mouse cultured neuronal cells were exposed to N-methyl-d-aspartate. Co-treatment with 1-OHPGE1 resulted in significant neuroprotection (P <0.05). To better understand potential mechanisms of action and to test whether changes in cyclic adenosine monophosphate (cAMP) levels and downstream signaling would be neuroprotective, we measured cAMP levels in primary neuronal cells. Brief exposure to 1-OHPGE1 increased cAMP levels more than twofold and increased the phosphorylation of extracellular-regulated kinases at positions Thr-202/Tyr-204. In a separate cohort of animals, 1-OHPGE1 at all doses tested produced no significant effect on the physiological parameters of core body temperature, mean arterial pressure and relative cerebral blood flow observed following drug treatment. Together, these results suggest that modulation of PGE2 receptors that increase cAMP levels and activate extracellular-regulated kinases 1/2 caused by treatment with 1-OHPGE1 can be protective against neuronal injury induced by focal ischemia.

AB - Differential neurological outcomes due to prostaglandin E2 activating G-protein-coupled prostaglandin E (EP) receptors have been observed. Here, we investigated the action of the EP4/EP3 agonist 1-hydroxyPGE1 (1-OHPGE1) in modulating transient ischemic brain damage. C57BL/6 mice were pretreated 50 min before transient occlusion of the middle cerebral artery with an intraventricular injection of 1-OHPGE1 (0.1, 0.2, 2.0 nmol/0.2 μL). Brain damage 4 days after reperfusion, as estimated by infarct volume, was significantly reduced by more than 19% with 1-OHPGE1 in the two higher-dose groups (P <0.05). To further address whether protection also was extended to neurons, primary mouse cultured neuronal cells were exposed to N-methyl-d-aspartate. Co-treatment with 1-OHPGE1 resulted in significant neuroprotection (P <0.05). To better understand potential mechanisms of action and to test whether changes in cyclic adenosine monophosphate (cAMP) levels and downstream signaling would be neuroprotective, we measured cAMP levels in primary neuronal cells. Brief exposure to 1-OHPGE1 increased cAMP levels more than twofold and increased the phosphorylation of extracellular-regulated kinases at positions Thr-202/Tyr-204. In a separate cohort of animals, 1-OHPGE1 at all doses tested produced no significant effect on the physiological parameters of core body temperature, mean arterial pressure and relative cerebral blood flow observed following drug treatment. Together, these results suggest that modulation of PGE2 receptors that increase cAMP levels and activate extracellular-regulated kinases 1/2 caused by treatment with 1-OHPGE1 can be protective against neuronal injury induced by focal ischemia.

KW - Agonist

KW - EP receptors

KW - Neuroprotection

KW - PGE

KW - Prostaglandins

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33644955960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644955960&partnerID=8YFLogxK

U2 - 10.1111/j.1460-9568.2005.04540.x

DO - 10.1111/j.1460-9568.2005.04540.x

M3 - Article

C2 - 16420413

AN - SCOPUS:33644955960

VL - 23

SP - 35

EP - 42

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 1

ER -